June 30, 2023

December 31, 2022

Assets

Current assets:

Cash and cash equivalents

$

13,484

$

20,644

Short-term investments

5,023

—

Accounts receivable and other receivables, net of allowance for doubtful accounts of
   $1 and $3 as of June 30, 2023 and December 31, 2022, respectively

630

1,287

Inventories, net — current

3,164

2,571

Assets held for sale

87

87

Prepaid expenses and other current assets

951

809

Total current assets

23,339

25,398

Property and equipment, net

560

704

Right of use asset

1,384

1,848

Inventories, net — noncurrent

1,297

767

Intangible assets, net

40

40

Other noncurrent assets

178

165

Total assets

$

26,798

$

28,922

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable and accrued expenses

$

2,783

$

2,881

Amounts due to related parties

33

48

Operating lease liability — current

993

1,010

Other current liabilities

282

270

Total current liabilities

4,091

4,209

Operating lease liability — noncurrent

532

1,007

Common stock warrant and option liabilities

2,445

806

Other noncurrent liabilities

2,000

2,000

Total liabilities

9,068

8,022

Commitments and contingencies (Note 13)

Stockholders’ equity:

Common stock, $0.001 par value—150,000,000 shares authorized as
   of June 30, 2023 and December 31, 2022; 1,108,432 and 616,079 shares issued
   and outstanding as of June 30, 2023 and December 31, 2022, respectively

65

65

Additional paid-in capital

284,202

278,827

Accumulated other comprehensive income

21

—

Accumulated deficit

(266,420

)

(257,859

)

Total stockholders’ equity

17,868

21,033

Non-controlling interest

(138

)

(133

)

Total stockholders' equity

17,730

20,900

Total liabilities and stockholders’ equity

$

26,798

$

28,922

Three Months Ended June 30,

Six Months Ended June 30,

2023

2022

2023

2022

Revenues:

Product

$

1,379

$

2,946

$

2,889

$

6,116

Royalty

—

50

—

100

License

10

862

10

862

Total revenues

1,389

3,858

2,899

7,078

Operating expenses (income):

Cost of revenues

981

3,447

1,806

6,906

Research and development

391

359

750

754

Gain on sale of Verdeca

—

(1,138

)

—

(1,138

)

Impairment of intangible assets

—

72

—

72

Change in fair value of contingent consideration

—

(39

)

—

(70

)

Impairment of property and equipment

—

346

—

346

Gain on sale of property and equipment

(7

)

(58

)

(26

)

(386

)

Selling, general and administrative

3,815

4,652

8,209

9,000

Total operating expenses

5,180

7,641

10,739

15,484

Loss from operations

(3,791

)

(3,783

)

(7,840

)

(8,406

)

Interest income

207

30

405

29

Other (loss) income, net

(13

)

(44

)

19

(3

)

Valuation loss on March 2023 PIPE

—

—

(6,076

)

—

Change in fair value of common stock warrant and option liabilities

4,416

—

5,357

—

Issuance and offering costs allocated to liability classified options

—

—

(430

)

(27

)

Net income (loss) before income taxes

819

(3,797

)

(8,565

)

(8,407

)

Income tax provision

(1

)

—

(1

)

—

Net income (loss)

818

(3,797

)

(8,566

)

(8,407

)

Net loss attributable to non-controlling interest

(5

)

(20

)

(5

)

(142

)

Net income (loss) attributable to common stockholders

$

823

$

(3,777

)

$

(8,561

)

$

(8,265

)

Net income (loss) per share attributable to common stockholders:

Basic and diluted

$

0.61

$

(6.81

)

$

(7.70

)

$

(14.90

)

Weighted-average number of shares used in per share
   calculations:

Basic and diluted

1,358,395

554,723

1,111,915

554,700

Other comprehensive income, net of tax

Unrealized gains on available-for-sale securities

$

21

$

—

$

21

$

—

Other comprehensive income

21

—

21

—

Comprehensive income (loss) attributable to common stockholders

$

844

$

(3,777

)

$

(8,540

)

$

(8,265

)

Six Months Ended June 30,

2023

2022

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss

$

(8,566

)

$

(8,407

)

Adjustments to reconcile net loss to cash used in operating activities:

Change in fair value of common stock warrant and option liabilities

(5,357

)

—

Change in fair value of contingent consideration

—

(70

)

Issuance and offering costs allocated to liability classified options

430

—

Valuation loss on March 2023 PIPE

6,076

—

Depreciation

138

277

Amortization of intangible assets

—

26

Lease amortization

357

420

Impairment of intangible assets

—

72

Gain on disposal of property and equipment

(26

)

(386

)

Stock-based compensation

411

583

Bad debt expense

—

37

Gain on sale of Verdeca

—

(1,138

)

Write-down of inventories

192

1,515

Impairment of property and equipment

—

346

Changes in operating assets and liabilities:

—

—

Accounts receivable and other receivables

87

(1,333

)

Inventories

(1,316

)

1,001

Prepaid expenses and other current assets

(142

)

(541

)

Other noncurrent assets

(13

)

15

Accounts payable and accrued expenses

(149

)

(247

)

Amounts due to related parties

(16

)

19

Other current liabilities

12

8

Other noncurrent liabilities

—

(1

)

Operating lease liabilities

(382

)

(446

)

Net cash used in operating activities

(8,264

)

(8,250

)

CASH FLOWS FROM INVESTING ACTIVITIES:

Proceeds from sale of property and equipment

37

841

Proceeds from sale of Verdeca — earn-out received

569

—

Purchases of property and equipment

(5

)

(46

)

Purchases of investments

(5,002

)

—

Net cash used by investing activities

(4,401

)

795

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock, pre-funded warrants and
   preferred investment options from March 2023 PIPE

5,997

—

Payments of offering costs relating to March 2023 PIPE

(497

)

—

Proceeds from ESPP purchases

5

4

Net cash provided by financing activities

5,505

4

Net decrease in cash and cash equivalents

(7,160

)

(7,451

)

Cash and cash equivalents — beginning of period

20,644

28,685

Cash and cash equivalents — end of period

$

13,484

$

21,234

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for interest

$

—

$

1

NONCASH INVESTING AND FINANCING ACTIVITIES:

Common stock warrant liabilities reclassified to equity
    upon adoption of ASU 2020-06

$

—

$

3,392

Common stock options issued to placement agent and included in offering
    costs related to March 2023 PIPE

$

212

$

—

Warrant and option modifications included in Valuation loss on March
    2023 PIPE

$

404

$

—

Proceeds from sale of property and equipment in accounts receivable and other receivables

$

2

$

51